## PCT POWER OF ATTORNEY

Duplicate of Original

0-1	PCT Power of Attorney (for an international application filed under the Patent Cooperation Treaty) (PCT Rule 90.4)	,
0-1-1	Prepared Using	PCT-SAFE [EASY mode] Version 3.50 (Build 0002.163)
1	The undersigned applicant(s)	VAN DUN, Jacobus, Alphonsus, Josephus; SOMERS, Maria, Victorina, Francisca; WOUTERS, Walter, Boudewijn, Leopold
1-1-1	hereby appoints (appoint) the following person	JANSSEN PHARMACEUTICA N.V. Turnhoutseweg 30 2340 Beerse Belgium
1-2	as	common representative
1-3	to represent the undersigned before	all the competent International Authorities
1-4	in connection with the international application identified below:	
1-4-1	Title of Invention	SUBSTITUTED 6-CYCLOHEXYLALKYL SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS
1-4-2	Applicant's or agent's file reference	PRD2122-PCT
1-4-3	International application number (if already available)	,
1-4-4	filed with the following Office as receiving Office	European Patent Office (EPO) (RO/EP)
1-5	and to make or receive payments on behalf of the undersigned	
2-1	Signature of applicant, agent or common representative	
-1-1	Name (LAST, First)	VAN DUN, Jacobus, Alphonsus, Josephus
-1-2	Name of signatory	, , , , , , , , , , , , , , , , , , ,
-1-3	Capacity	
1-2	Signature of applicant, agent or common representative	Y Colo
-2-1	Name (LAST, First)	SOMERS, Maria, Victorina, Francisca
2-2	Name of signatory	
-2-3	Capacity	
-3	Signature of applicant, agent or common representative	1
3-1	Name (LAST, First)	WOUTERS, Walter, Boudewijn, Leopold
	Name of signatory	
-3-2 -3-3	Capacity	20 December 2004 (20.12,2004)

## 1/1

## **Duplicate of Original**

	**	
0-1	PCT Power of Attorney (for an international application filed under the Patent Cooperation Treaty) (PCT Rule 90.4)	
0-1-1	Prepared Using	PCT-SAFE [EASY mode] Version 3.50 (Build 0002.163)
		1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
1	The undersigned applicant(s)	MABIRE, Dominique, Jean-Pierre
1-1-1	hereby appoints (appoint) the following person	JANSSEN PHARMACEUTICA N.V. Turnhoutseweg 30 2340 Beerse Belgium
1-2	as	common representative
1-3	to represent the undersigned before	all the competent International Authorities
1-4	in connection with the international application identified below:	
1-4-1	Title of Invention	SUBSTITUTED 6-CYCLOHEXYLALKYL SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS
1-4-2	Applicant's or agent's file reference	PRD2122-PCT
1-4-3	International application number (if already available)	
1-4-4	filed with the following Office as receiving Office	European Patent Office (EPO) (RO/EP)
1-5	and to make or receive payments on behalf of the undersigned	
2-1	Signature of applicant, agent or common representative	16
		1
2-1-1	Name (LAST, First)	MABIRE, Dominique, Jean-Pierre
2-1-2	Name of signatory	
2-1-3	Capacity	
3	Date	20 December 2004 (20.12.2004)

VIII-2-1	Declaration: Entitlement to apply for and be granted a patent Doclaration as to the applicant's entitlement, as at the international filing date, to apply for and be granted a patent (Rules 4.17(i) and 5 bis.1(a)(ii), in a case where the doclaration under Rule 4.17(ii) is not appropriate:	in relation to the international application No. PCT/EP2004/013165
	Name (LAST, First)	JANSSEN PHARMACEUTICA N.V. is entitled to apply for and be granted a patent by virtue of the following:
VIII-2-1(i v)		an assignment from MABIRE, Dominique, Jean-Pierre to Janssen-Cilag, dated 20 October 2004 (20.10.2004)
VIII-2-1(i i)		JANSSEN PHARMACEUTICA N.V. is entitled as employer of the inventor, VAN DUN, Jacobus, Alphonsus, Josephus
VIII-2-1(i i)		JANSSEN PHARMACEUTICA N.V. is entitled as employer of the inventor, SOMERS, Maria, Victorina, Francisca
VIII-2-1(i i)		JANSSEN PHARMACEUTICA N.V. is entitled as employer of the inventor, WOUTERS, Walter, Boudewijn, Leopold
VIII-2-1(i v)		an assignment from Janssen-Cilag to JANSSEN PHARMACEUTICA N.V., dated 20 October 2004 (20.10.2004)
	This declaration is made for the purposes of:	all designations except the designation of the United States of America

VIII-3-1	Declaration: Entitlement to claim priority  Doctaration as to the applicant's  entitlement, as at the international filing  date, to daim the priority of the earlier  applicant is not the applicant who filed  applicant is not the applicant who filed  the earlier application or where the  applicant of the mac shanged since the  filling of the earlier application (Rufes  4.170) and of Shin. (Ja(iiii))	in relation to the international application No. PCT/EP2004/013165
	Name	JANSSEN PHARMACEUTICA N.V.
		is entitled to claim priority of earlier application No. 03078918.4 by virtue of the following:
VIII-3-1(i v)		an assignment from MABIRE, Dominique, Jean-Pierre to Janssen-Cilag, dated 20 October 2004 (20.10.2004)
VIII-3-1(i i)		JANSSEN PHARMACEUTICA N.V. is entitled as employer of the inventor, VAN DUN, Jacobus, Alphonsus, Josephus
VIII-3-1(i i)		JANSSEN PHARMACEUTICA N.V. is entitled as employer of the inventor, SOMERS, Maria, Victorina, Francisca
VIII-3-1(i i)		JANSSEN PHARMACEUTICA N.V. is entitled as employer of the inventor, WOUTERS, Walter, Boudewijn, Leopold
VIII-3-1(i v)		an assignment from Janssen-Cilag to JANSSEN PHARMACEUTICA N.V., dated 20 October 2004 (20.10.2004)
	This declaration is made for the purposes of:	all designations

-VIII-4-1	the purposes of the designation of the United States of America of the United States of America:	I hereby declare that I believe I am the original, first and sole (if only one inventor is listed below) or joint (if more than one inventor is listed below) inventor of the subject matter which is claimed and for which a patent is sought.  This declaration is directed to international application PCT/EP2004/013165 (if furnishing declaration pursuant to Rule 26ter).  I hereby declare that my residence, madling address, and citizenship are as stated next to my name.  I hereby state that I have reviewed and understand the contents of the above-identified international application, including the claims of said application. I have identified in the request of said application, in compliance with PCT Rule 4.10, any claim to foreign priority, and I have identified below, under the heading "Prior Applications", by application mumber, country or Member of the World Trade Organization, day, month, and year of filing, any application for a patent or inventor's certificate filed in a country other than the United States of America, including any PCT international application designating at least one country other than the United States of America, having a filing date before that of the application on which foreign priority is claimed.
VIII-4-1- 1	Prior applications:	03078918.4, EP, 10 December 2003

		I hereby acknowledge the duty to disclose information that is known by me to be material to patentability as defined by 37 C.F.R. § 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the PCT international filing date of the continuation-in-part application.  I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.
VIII-4-1- 1-1	Name (LAST, First)	MABIRE, Dominique, Jean-Pierre
	Residence: (city and either US State, if applicable, or country)	La Ferté Macé, France
1-3	Mailing address:	Janssen-Cilag Campus de Maigremont F- 27100 Val de Reuil France
VIII-4-1- 1-4	Citizenship:	FR , /
1-5	Inventor's Signature: (if not contained in the request, or if declaration is corrected or added under Rule 20ter after the filling of the international application. The signature must be that of the inventor, not that of the agent)	-4-1
	Date: (of signature which is not contained in the request, or of the declaration that is corrected or added under Rule 26ter after the filling of the international application)	January 31, 2005

2-1	- Name (LAST, First)	VAN DUN, Jacobus, Alphonsus, Josephus
VIII-4-1 2-2	<ul> <li>Residence: (city and either US State, if applicable, or country)</li> </ul>	Kasterlee, Belgium
VIII-4-1- 2-3	- Mailing address:	Janssen Pharmaceutica N.V. Turnhoutseweg 30 B-2340 Beerse Belgium
VIII-4-1- 2-4	- Citizenship:	BE
VIII-4-1- 2-5	Inventor's Signature: (if not contained in the request, or if declaration is corrected or added under Rule 26ter after the filing of the international application. The signature must be that of the inventor, not that of the agent)	
VIII-4-1- 2-6	(of signature which is not contained in the request, or of the declaration that is corrected or added under Rule 26ter after the filing of the international application)	1212010
VIII-4-1- 3-1	Name (LAST, First)	SOMERS, Maria, Victorina, Francisca
VIII-4-1- 3-2	Residence: (city and either US State, if applicable, or country)	Vosselaar, Belgium
3-3	Mailing address:	Janssen Pharmaceutica N.V. Turnhoutseweg 30 B-2340 Beerse Belgium
VIII-4-1- 3-4	Citizenship:	BE
VIII-4-1- 3-5 VIII-4-1- 3-6	(of signature which is not contained in	Hair
-	the request, or of the declaration that is corrected or added under Rule 26ter after the filing of the international application)	12/21/04
4-1	Name (LAST, First)	WOUTERS, Walter, Boudewijn, Leopold
4-2	Residence: (city and either US State, if applicable, or country)	Kapellen, Belgium
4-3	Mailing address:	Janssen Pharmaceutica N.V. Turnhoutseweg 30 B-2340 Beerse Belgium
4-4		BE
4-5	Inventor's Signature: (if not contained in the request, or if declaration is corrected or added under Rule 26ter after the filling of the international application. The signature must be that of the inventor, not that of the agent)	
	Date (of signature which is not contained in the request, or of the declaration that is corrected or added under Rule 26ter after the filing of the international application)	12/21/04